Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Application of Protein Capsular Matrix Vaccine Technology to the Development of a Novel Form of Killed Whole Cell Vaccines

FY 2013-14

Summary
Immunization is the most effective public health tool available to control infectious disease, and is extremely cost effective compared to disease treatment. Making vaccines widely available requires the manufacturing to be inexpensive and simplistic. Live attenuated bacteria can be used as vaccines, and while highly successful, have drawbacks such as manufacturing problems, low stability, and causing disease. Killed bacterial vaccines are easier to manufacture, but typically do not provide long term protection against infection. Conjugate vaccines are composed of two parts bound together; a polysaccharide (PS), which is a major protective structure covering the surface of many bacteria cells, and a protein, which can trigger an immune response. Conjugate vaccines have been some of the most successful vaccines currently used, and are protective for infants and toddlers. However, this technology is expensive and therefore is unlikely to become available to the developing world. However, a novel alternative to conventional conjugate vaccines is Protein Capsule Matrix Vaccine (PCMV) technology. PCMV uses the same components as conjugate vaccines, but instead of directly attaching them together, only the protein is linked into a mesh net, trapping the PS inside it. This technology has been shown to be effective as a vaccine in mice Our strategy is to simplify the PCMV strategy. Instead of purifying the PS from bacteria, whole cell bacteria will be used. We will work on optimizing conditions to produce the conjugate-like vaccines against Vibrio cholerae, Salmonella typhi, and Streptococcus pneumoniae, and test them in mice for immune responses and protection against disease. We will also compare our vaccines to commercially available ones, to determine their effectiveness. Our goal is to develop a new class of vaccine which is more effective, safer, and easier to produce than currently available vaccines
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
300237
Name
Iwashkiw Jeremy A
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Application of Protein Capsular Matrix Vaccine Technology to the Development of a Novel Form of Killed Whole Cell Vaccines
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Glycobiology; Infectious Diseases; Microbiology; Molecular Biology; Proteomics; Vaccine
Abstract
Immunization is the most effective public health tool available to control infectious disease, and is extremely cost effective compared to disease treatment. Making vaccines widely available requires the manufacturing to be inexpensive and simplistic. Live attenuated bacteria can be used as vaccines, and while highly successful, have drawbacks such as manufacturing problems, low stability, and causing disease. Killed bacterial vaccines are easier to manufacture, but typically do not provide long term protection against infection. Conjugate vaccines are composed of two parts bound together; a polysaccharide (PS), which is a major protective structure covering the surface of many bacteria cells, and a protein, which can trigger an immune response. Conjugate vaccines have been some of the most successful vaccines currently used, and are protective for infants and toddlers. However, this technology is expensive and therefore is unlikely to become available to the developing world. However, a novel alternative to conventional conjugate vaccines is Protein Capsule Matrix Vaccine (PCMV) technology. PCMV uses the same components as conjugate vaccines, but instead of directly attaching them together, only the protein is linked into a mesh net, trapping the PS inside it. This technology has been shown to be effective as a vaccine in mice Our strategy is to simplify the PCMV strategy. Instead of purifying the PS from bacteria, whole cell bacteria will be used. We will work on optimizing conditions to produce the conjugate-like vaccines against Vibrio cholerae, Salmonella typhi, and Streptococcus pneumoniae, and test them in mice for immune responses and protection against disease. We will also compare our vaccines to commercially available ones, to determine their effectiveness. Our goal is to develop a new class of vaccine which is more effective, safer, and easier to produce than currently available vaccines
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Iwashkiw, Jeremy A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2013-14) | Canada Spends